Clariane Shares Drop to €4.11 on Monday, Weighed Down by Surge in Long-Term Rates
The stock of the nursing home specialist significantly fell this Monday morning to €4.11, in a Parisian market that was also in the red. The stock is among the largest declines in the SBF 120.
Clariane Under Pressure at €4.11 in a Market Dragged Down by Long-Term Rates
Clariane's stock fell 3.48% to €4.11 by midday, compared to €4.258 at the last close. The stock is among the largest declines in the SBF 120, in an index that is down 0.73% during the session. The CAC 40 is down 0.69% at the same time. The market context is heavy. The yield on the 10-year US Treasury climbed to 4.63%, its highest since February 2025, and the 10-year Japanese bond reached 2.80%, a level not seen since 1996. This surge in long-term rates mechanically weighs on the most indebted stocks, including nursing home operators. Clariane had just launched a senior bond issue of 230 million euros at 6.875% in late April to refinance part of its hybrid debt, in an already tense financing environment. The rebound of Brent above 110 dollars a barrel, linked to the war in Iran and the blockade of the Strait of Hormuz, fuels the fear of persistently higher inflation and reinforces the scenario of 'higher for longer' interest rates. Competitor Emeis is down 3.76% at the same time, indicating broader sector pressure. The one-month volatility of the stock remains contained at 13.57%.
The Stock Remains Above Its Moving Averages and Keeps +10% Over a Year
Despite today's setback, the medium-term configuration remains oriented. The price at €4.11 stays above the MM20 (€4.06), MM50 (€3.85), and MM200 (€3.98). The gap with the 50-day average is still at 6.75%, indicating that the spring momentum is not broken. The RSI at 61 remains in a neutral zone. The decline brings the stock to the middle of the Bollinger Bands, at 57% of the amplitude. The management 2026 was marked by organic growth of 4.9% in the first quarter and the confirmation of the 2023-2026 and 2025-2028 targets. Based on the consensus of analysts, the stock is trading at about 59.7 times the expected earnings for the current fiscal year and 13.2 times those of the following year, with the market incorporating a BPA growth of 353% between the two fiscal years. For comparison, the Health Care sector is valued on average at 21.9 times the earnings of the current fiscal year. The identified support threshold is at €3.66, resistance at €4.35. Over a year, the performance remains positive at +10.07%. Next financial calendar appointment: the first half of 2026 results on July 29.
